Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

A method for treating melanoma, comprising administering to a patient having melanoma an effective amount of a compound of formula (I):

• or a pharmaceutically acceptable salt, tautomer, stereoisomer or enantiomer thereof,
• wherein:
• R1 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;
• R2 is H or substituted or unsubstituted C1-3 alkyl;
• R3 is phenyl, substituted with one or more halogen, optionally further substituted with one or more substituents independently selected from substituted or unsubstituted C1-3 alkyl, CN, and —OR′, wherein each R′ is independently substituted or unsubstituted C1-3 alkyl;
• wherein when an alkyl group is substituted, it is substituted with a substituent selected from the group consisting of chloro;
• iodo;
• bromo;
• fluoro;
• alkyl;
• hydroxyl;
• alkoxy;
• alkoxyalkyl;
• amino;
• alkylamino;
• carboxy;
• nitro;
• cyano;
• thiol;
• thioether;
• imine;
• imide;
• amidine;
• guanidine;
• enamine;
• aminocarbonyl;
• acylamino;
• phosphonate;
• phosphine;
• thiocarbonyl;
• sulfinyl;
• sulfone;
• sulfonamide;
• acyl;
• ester;
• urea;
• urethane;
• oxime;
• hydroxyl amine;
• alkoxyamine;
• aryloxyamine, aralkoxyamine;
• N-oxide;
• hydrazine;
• hydrazide;
• hydrazone;
• azide;
• isocyanate;
• isothiocyanate;
• cyanate;
• thiocyanate;
• B(OH)2;
• and O(alkyl)aminocarbonyl;
• wherein when a group other than an alkyl group is substituted, it is substituted with a substituent selected from the group consisting of chloro;
• iodo;
• bromo;
• fluoro;
• alkyl;
• hydroxyl;
• alkoxy;
• alkoxyalkyl;
• amino;
• alkylamino;
• carboxy;
• nitro;
• cyano;
• thiol;
• thioether;
• imine;
• imide;
• amidine;
• guanidine;
• enamine;
• aminocarbonyl;
• acylamino;
• phosphonate;
• phosphine;
• thiocarbonyl;
• sulfinyl;
• sulfone;
• sulfonamide;
• acyl;
• ester;
• urea;
• urethane;
• oxime;
• hydroxylamine;
• alkoxyamine;
• aryloxyamine;
• aralkoxyamine;
• N-oxide;
• hydrazine;
• hydrazide;
• hydrazone;
• azide;
• isocyanate;
• isothiocyanate;
• cyanate;
• thiocyanate;
• oxo;
• B(OH)2, O(alkyl)aminocarbonyl;
• cycloalkyl, which may be monocyclic or fused or non-fused polycyclic, or a heterocyclyl, which may be monocyclic or fused or non-fused polycyclic;
• monocyclic or fused or non-fused polycyclic aryl or heteroaryl;
• aryloxy;
• aralkyloxy;
• heterocyclyloxy;
• and heterocyclylalkoxy;
• and
• provided that the compound is not
• 4-[2-[(1-methylethyl)amino]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-9-yl]-cis-cyclohexanecarboxamide, or
• 4-[8-[(2,4-difluorophenyl)amino]-2-[(trans-4-hydroxycyclohexyl)amino]-9H-purin-9-yl]-cis-cyclohexanecarboxamide,
• wherein said compound of formula (I) is administered to said patient one to four times a day in a dose of about 0.005 mg/kg to about 10 mg/kg of said patient's body weight.